The prognostic value of laboratory parameters referring to hemopoietic stress in patients with COVID-19—a single center experience

In the present study we attempted to assess whether a relationship exists between laboratory signs of hemopoietic stress and fatal outcome in coronavirus disease (COVID)-19—positive intensive care unit (ICU) and non-ICU patients. Prospectively collected data of 206 COVID-19 patients (95 ICU and 111 non-ICU) were retrospectively analyzed. Beside comparing routine laboratory parameters, the analysis focused on nucleated red blood cell count (NRBC), red cell distribution width (RCDW), immature granulocyte count (IG), mean platelet volume (MPV) and platelet distribution width (PDW). In the total COVID cohort higher NRBC, RCDW, IG, MPV and PDW values were observed in patients with fatal outcome as compared to survivors. Significant differences could be observed between non-ICU and critically ill patients in NRBC (medians and interquartile range (IQR): 10/0–20/ vs. 20/10–60/ g/L, p < 0.001), IG (0.16/0.04–0.39/ vs. 0.42 /0.20–0.75/ g/L, p < 0.001), MPV (10.9 ± 1.2 vs. 11.4 ± 1.2 fL, p < 0.01) and PDW (14.5/11.6-44.7/ vs. 19.9/13.7–57.7/ fL, p < 0.001), respectively. In the ICU subgroup, RDW and MPV were higher among patients who died. Severe acute respiratory syndrome after coronavirus infection (SARS-CoV-2 infection) causes perturbation of hemopoiesis. Laboratory parameters referring to hemopoietic stress may serve as useful predictors of poor outcome in hospitalized COVID-19 patients needing intensive care.

SARS-CoV infection; Hemopoietic stress; Intensive care

[1] Johns Hopkins University Coronavirus Resource Center. 2021. Available at: https://coronavirus.jhu.edu/. (Accessed: 26 June 2021).

[2] Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. The BMJ. 2020; 370: m3339.

[3] Galloway JB, Norton S, Barker RD, Brookes A, Carey I, Clarke BD, et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study. Journal of Infection 2020; 81: 282–288.

[4] Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58: 1021–1028.

[5] Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58: 1131–1134.

[6] Linssen J, Ermens A, Berrevoets M, Seghezzi M, Previtali G, van der Sar-van der Brugge S, et al. A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study. eLife. 2020; 9: e63195.

[7] Kiss S, Gede N, Hegyi P, Németh D, Földi M, Dembrovszky F, et al. Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis. Medical Microbiology and Immunology. 2021; 210: 33–47.

[8] Pfeifer M, Ewig S, Voshaar T, Randerath W, Bauer T, Geiseler J, et al. Position paper for the state of the art application of respiratory support in patients with COVID-19. Pneumologie. 2020; 74: 337–357.

[9] Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Frontiers in Immunology. 2020; 11: 1626.

[10] Schwartz SO, Stansbury F. Significance of nucleated red blood cells in peripheral blood: analysis of 1496 cases. Journal of the American Medical Association. 1954; 154: 1339–1340.

[11] Tóth J, Debreceni IB, Berhés M, Hajdú E, Deák Á, Pető K, et al. Red blood cell and platelet parameters are sepsis predictors in an Escherichia coli induced lethal porcine model. Clinical Hemorheology and Microcirculation. 2017; 66: 249–259.

[12] Stachon A, Sondermann N, Imohl M, Krieg M. Nucleated red blood cells indicate high risk for in-hospital mortality. Journal of Laboratory and Clinical Medicine. 2002; 140: 407–412.

[13] Stachon A, Kempf R, Holland-Letz T, Friese J, Becker A, Krieg M. Daily monitoring of nucleated red blood cells in the blood of surgical intensive care patients. Clinica Chimica Acta. 2006; 366: 329–335.

[14] Stachon A, Segbers E, Holland-Letz T, Kempf R, Hering S, Krieg M. Nucleated red blood cells in the blood of medical intensive care patients indicate increased mortality risk: a prospective cohort study. Critical Care. 2007; 11: R62.

[15] Purtle SW, Horkan CM, Moromizato T, Gibbons FK, Christopher KB. Nucleated red blood cells, critical illness survivors and postdischarge outcomes: a cohort study. Critical Care. 2017; 21: 154.

[16] Menk M, Giebelhäuser L, Vorderwülbecke G, Gassner M, Graw JA, Weiss B, et al. Nucleated red blood cells as predictors of mortality in patients with acute respiratory distress syndrome (ARDS): an observational study. Annals of Intensive Care. 2018; 8: 42.

[17] Foy BH, Carlson JCT, Reinertsen E, Padros I Valls R, Pallares Lopez R, Palanques-Tost E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Network Open. 2020; 3: e2022058.

[18] Bommenahalli Gowda S, Gosavi S, Ananda Rao A, Shastry S, Raj SC, Menon S, et al. Prognosis of COVID-19: red cell distribution width, platelet distribution width, and C-reactive protein. Cureus. 2021; 13: e13078.

[19] Parra-Izquierdo I, Aslan JE. Perspectives on platelet heterogeneity and host immune response in coronavirus disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis. 2020; 46: 826–830.

[20] Zhong Q, Peng J. Mean platelet volume/platelet count ratio predicts se-vere pneumonia of COVID‐19. Journal of Clinical Laboratory Analysis. 2021; 35: e23607.

[21] Lê VB, Schneider JG, Boergeling Y, Berri F, Ducatez M, Guerin J, et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. American Journal of Respiratory and Critical Care Medicine. 2015; 191: 804–819.

[22] Lippi G, Henry BM, Favaloro EJ. Mean platelet volume predicts severe COVID-19 illness. Semin Thromb Hemost. 2021; 47: 456–459.

[23] Li J, Li Y, Sheng X, Wang F, Cheng D, Jian G, et al. Combination of mean platelet volume/platelet count ratio and the APACHE II score better predicts the short-term outcome in patients with acute kidney injury receiving continuous renal replacement therapy. Kidney and Blood Pressure Research. 2018; 43: 479–489.

[24] Wang Y, Fan Z, Wang S, Zhuang C. The diagnostic value of platelet distribution width in patients with mild COVID‐19. Journal of Clinical Laboratory Analysis. 2021; 35: e23703.

[25] Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. American Journal of Hematology. 2021; 96: 471–479.